HBV-related complications after HBV reactivation.
(A) Impaired liver function; (B) liver cirrhosis; (C) HBV-related hepatic failure; (D) HBV-related death. HBV, hepatitis b virus.
Saifu Yin (8160654) +4 more
core +1 more source
Suppression of HBV by Tenofovir in HBV/HIV coinfected patients : a systematic review and meta-analysis [PDF]
Background: Hepatitis B coinfection is common in HIV-positive individuals and as antiretroviral therapy has made death due to AIDS less common, hepatitis has become increasingly important. Several drugs are available to treat hepatitis B. The most potent
Thomas Reiberger +93 more
core +2 more sources
The Impact of External Debt on Economic Growth in OIC Countries: A Panel Data Analysis [PDF]
In recent decades, the OIC countries have experienced substantial variations in external debt levels, frequently driven by global economic trends and regional conflicts.
Nuran Halise Belet
doaj +1 more source
Viral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV) infection, and adaptation is greatest in HBV e antigen-negative disease [PDF]
Hepatitis B virus (HBV)-specific T-cell responses are important in the natural history of HBV infection. The number of known HBV-specific T-cell epitopes is limited, and it is not clear whether viral evolution occurs in chronic HBV infection. We aimed to
Chopra, A. +56 more
core +1 more source
NAFLD‐related hepatocellular carcinoma: The growing challenge
Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah +2 more
wiley +1 more source
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou +13 more
wiley +1 more source
Changes in viral load and HBsAg and HBeAg status with age in HBV chronic carriers in The Gambia. [PDF]
BACKGROUND: Little is known about changes in hepatitis B viral load (HBV DNA) in relation to age in Africa. The aim of this study is to determine the natural course of HBV chronic infection, particularly in relation to sequential changes in serum HBV DNA
Jeffries, David +31 more
core +1 more source
Proteogenomic characterization of cholangiocarcinoma
Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng +18 more
wiley +1 more source
NanoAPC deliver antigen, IL-2 and co-stimulatory molecules to antigen specific T cells and activate viral specific T cells in chronic infections [PDF]
This thesis was submitted for the degree of Doctor of Philosophy and awarded by Brunel University.The study of the immune system has provided insight in the mechanism of protection induced by vaccination; primarily that most clinically protective ...
Liu, Mengya
core +7 more sources
HBV-CARE Networking Day Report.docx
A systematic report of the HBV-CARE (Clinicians, Advocates and Researchers Exchange) group networking day held at The Francis Crick Institute.
Marion Delphin (11921561) +2 more
core +1 more source

